A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.

5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) - Beckley Psytech

http://www.ncbi.nlm.nih.gov/pubmed/41761045

Adeep Puri; Anna O Ermakova; Catherine Bird; Claire Roberts; Fiona Dunbar; Hattie Wells; James J Rucker; Mathieu Seynaeve

Feb 28, 2026